Phase 2 Breast Cancer Trial, Recruiting NCT03474822 Sponsor: CAS Lamvac Biotech Co., Ltd. Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT03474822
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old (male or female)
  • You have been diagnosed with advanced breast cancer or advanced liver cancer, confirmed by tissue biopsy and imaging scans, with at least one clearly measurable tumour visible on scans
  • You have already received at least one standard cancer treatment before
  • If you had chemotherapy or radiation therapy, it ended at least 1 month ago; if you had targeted drug therapy, enough time has passed since stopping (confirm with trial site for your specific drug)
  • Your general activity level is rated as fully active or only slightly restricted (confirm with trial site)
  • You are expected to live for at least 6 months
  • Your blood counts (platelets, white blood cells, and haemoglobin) meet certain minimum levels, and you do not have certain types of anaemia such as iron deficiency or thalassemia (confirm with trial site)
  • Your immune cells, immune function, and heart, lung, liver, and kidney function are at or close to normal levels
  • You are willing and able to attend follow-up appointments as required
  • You are able to understand the study and sign a consent form

Who may not be able to join:

  • You have a serious blood disorder affecting haemoglobin, or a severe deficiency of an enzyme called G6PD
  • You have had your spleen removed or have an enlarged spleen
  • You have a drug addiction or are dependent on alcohol
  • You have a serious or uncontrolled illness, such as an active infection, severely high blood pressure, unstable chest pain, heart failure, serious heart rhythm problems, or significant liver or kidney problems
  • You have a known history of a neurological (brain/nerve) or psychiatric (mental health) condition
  • You are currently receiving any other cancer treatment at the same time as this trial
  • Your immune system function is significantly lower than normal
  • Your lung function is seriously impaired, you are unable to get out of bed, or you feel breathless even at rest
  • You have advanced liver cancer with severely enlarged veins in your oesophagus (food pipe)
  • You have a persistent severe cough, difficulty breathing, are unable to eat normally, or are unable to cooperate with the study procedures
  • Your overall physical condition is too poor to tolerate the treatment, in the opinion of the research team
  • You are pregnant or breastfeeding
  • You are a woman of childbearing age with a positive pregnancy test
  • The research team has any other reason to believe this study is not suitable for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
CAS Lamvac Biotech Co., Ltd.
Registry
ClinicalTrials.gov
Start date
10 August 2018
Est. completion
30 June 2023

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov